Patients who have undergone prior chemotherapeutic regimens, such as docetaxel or cabazitaxel, often present with more aggressive and resistant tumor phenotypes, which can adversely affect the efficacy of subsequent 177Lu-PSMA treatment [14]. A recent systematic review and meta-analysis evaluated the impact of prior taxane chemotherapy on the efficacy of 177Lu-PSMA radioligand therapy in patients with mCRPC [9]. The gene discussed is FOLH1; the disease is neoplasm.